GLANCE–H&N Study
Research type
Research Study
Full title
Global Treatment Patterns, Health Care Resource Utilization, and Survival Outcomes among Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
IRAS ID
204629
Contact name
Kevin Harrington
Contact email
Sponsor organisation
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Duration of Study in the UK
0 years, 10 months, 1 days
Research summary
The GLANCE–H&N Study is a retrospective patient chart (note) review involving the collection of information already in patient medical records. Patients suffering from a type of cancer called Squamous Cell Carcinoma of the Head and Neck (HNSCC) will have started a first line systemic (injected into the patients' body or taken orally) therapy between 1st January, 2012 and 30th June, 2013 to treat the recurrence of this disease or the development of metastases.
Approximately 1,080 patients in total will participate at around 103 sites in Australia, Brazil, Canada, Germany, Italy, Spain, South Korea, Taiwan and the United Kingdom. Around 10 patients who meet the inclusion criteria, and to whom none of the exclusion criteria apply will be enrolled at each of the 12 eligible study sites in the UK.Information will be recorded on-line in electronic Case Report Forms (eCRFs) and will include demographic data, medical history, treatment history including the first line systemic therapy started between 1st January, 2012 and 30th June, 2013, health care resource utilisation and whether the patients’ are living or deceased at the time of the data collection.
Physicians (one from each site) who are responsible for the treatment of HNSCC patients will complete a questionnaire to document standard regimens and reasons for treatment choice or therapy discontinuation for each patient and line of therapy at each site.
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
16/WM/0409
Date of REC Opinion
25 Sep 2016
REC opinion
Further Information Favourable Opinion